North America Multiple Sclerosis Therapeutics Market
The North America Multiple Sclerosis Therapeutics Market size was valued at US$ 9,144.98 Mn in 2019 and is projected to reach US$ 15,269.74 Mn by 2027, growing at a CAGR of 6.8% during 2020 - 2027.
Report Coverage
- Drug Class: Immunosuppressant, Immunomodulators
- Route of Administration: Injectable, Oral
- Distribution Channel: Hospital Pharmacies, Retail Pharmacies, E-Commerce
US$ 9,144.98 Mn
Market size in 2019
US$ 15,269.74 Mn
Market Size by 2027
6.8%
CAGR, 2020 - 2027
2020-2027
Forecast Period
1. Introduction
1.1 Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Market Insights
2.2 Market Attractiveness
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Data Triangulation and Validation
4. North America Multiple Sclerosis Therapeutics Market Landscape
4.1 Overview
4.3 Ecosystem Analysis
- 4.3.1 List of Vendors in the Value Chain
5. North America Multiple Sclerosis Therapeutics Market – Key Market Dynamics
5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints
6. North America Multiple Sclerosis Therapeutics Market Regional Analysis
6.2 North America Multiple Sclerosis Therapeutics Market Revenue 2017-2027 (US$ Million)
6.3 North America Multiple Sclerosis Therapeutics Market Forecast Analysis
7. North America Multiple Sclerosis Therapeutics Market Analysis – by Drug Class
7.1 Immunosuppressant
- 7.1.1 Overview
- 7.1.2 Immunosuppressant: North America Multiple Sclerosis Therapeutics Market – Revenue and Forecast, 2017-2027 (US$ Million)
7.2 Immunomodulators
- 7.2.1 Overview
- 7.2.2 Immunomodulators: North America Multiple Sclerosis Therapeutics Market – Revenue and Forecast, 2017-2027 (US$ Million)
8. North America Multiple Sclerosis Therapeutics Market Analysis – by Route of Administration
8.1 Injectable
- 8.1.1 Overview
- 8.1.2 Injectable: North America Multiple Sclerosis Therapeutics Market – Revenue and Forecast, 2017-2027 (US$ Million)
8.2 Oral
- 8.2.1 Overview
- 8.2.2 Oral: North America Multiple Sclerosis Therapeutics Market – Revenue and Forecast, 2017-2027 (US$ Million)
9. North America Multiple Sclerosis Therapeutics Market Analysis – by Distribution Channel
9.1 Hospital Pharmacies
- 9.1.1 Overview
- 9.1.2 Hospital Pharmacies: North America Multiple Sclerosis Therapeutics Market – Revenue and Forecast, 2017-2027 (US$ Million)
9.2 Retail Pharmacies
- 9.2.1 Overview
- 9.2.2 Retail Pharmacies: North America Multiple Sclerosis Therapeutics Market – Revenue and Forecast, 2017-2027 (US$ Million)
9.3 E-Commerce
- 9.3.1 Overview
- 9.3.2 E-Commerce : North America Multiple Sclerosis Therapeutics Market – Revenue and Forecast, 2017-2027 (US$ Million)
10. North America Multiple Sclerosis Therapeutics Market – North America Analysis
10.1 Overview
10.2 North America- 10.2.1 North America Multiple Sclerosis Therapeutics Market Breakdown, by Key Country, 2020 and 2027 (%)
- 10.2.1.1 North America Multiple Sclerosis Therapeutics Market – Revenue and Forecast Analysis – by Country
- 10.2.1.1 US: North America Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
- 10.2.1.1.1 US: North America Multiple Sclerosis Therapeutics Market Breakdown, by Drug Class
- 10.2.1.1.2 US: North America Multiple Sclerosis Therapeutics Market Breakdown, by Route of Administration
- 10.2.1.1.3 US: North America Multiple Sclerosis Therapeutics Market Breakdown, by Distribution Channel
- 10.2.1.2 Canada: North America Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
- 10.2.1.2.1 Canada: North America Multiple Sclerosis Therapeutics Market Breakdown, by Drug Class
- 10.2.1.2.2 Canada: North America Multiple Sclerosis Therapeutics Market Breakdown, by Route of Administration
- 10.2.1.2.3 Canada: North America Multiple Sclerosis Therapeutics Market Breakdown, by Distribution Channel
- 10.2.1.3 Mexico : North America Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
- 10.2.1.3.1 Mexico : North America Multiple Sclerosis Therapeutics Market Breakdown, by Drug Class
- 10.2.1.3.2 Mexico : North America Multiple Sclerosis Therapeutics Market Breakdown, by Route of Administration
- 10.2.1.3.3 Mexico : North America Multiple Sclerosis Therapeutics Market Breakdown, by Distribution Channel
11. Competitive Landscape
11.1 Heat Map Analysis
11.2 Company Positioning and Concentration
12. Industry Landscape
12.1 Overview
12.2 Market Initiative
12.3 Partnerships and Collaborations
12.4 Other Developments
13. Company Profiles
13.1 Merck & Co., Inc.
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
13.2 Novartis AG
- 13.2.1 Key Facts
- 13.2.2 Business Description
- 13.2.3 Products and Services
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
13.3 Bayer AG
- 13.3.1 Key Facts
- 13.3.2 Business Description
- 13.3.3 Products and Services
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
13.4 Sanofi
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Products and Services
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
13.5 Bristol-Myers Squibb Company
- 13.5.1 Key Facts
- 13.5.2 Business Description
- 13.5.3 Products and Services
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
13.6 Horizon Therapeutics plc
- 13.6.1 Key Facts
- 13.6.2 Business Description
- 13.6.3 Products and Services
- 13.6.4 Financial Overview
- 13.6.5 SWOT Analysis
- 13.6.6 Key Developments
13.7 TEVA PHARMACEUTICAL INDUSTRIES LTD
- 13.7.1 Key Facts
- 13.7.2 Business Description
- 13.7.3 Products and Services
- 13.7.4 Financial Overview
- 13.7.5 SWOT Analysis
- 13.7.6 Key Developments
13.8 Takeda Pharmaceutical Company Limited
- 13.8.1 Key Facts
- 13.8.2 Business Description
- 13.8.3 Products and Services
- 13.8.4 Financial Overview
- 13.8.5 SWOT Analysis
- 13.8.6 Key Developments
13.9 F. HOFFMANN-LA ROCHE LTD
- 13.9.1 Key Facts
- 13.9.2 Business Description
- 13.9.3 Products and Services
- 13.9.4 Financial Overview
- 13.9.5 SWOT Analysis
- 13.9.6 Key Developments
13.10 Biogen
- 13.10.1 Key Facts
- 13.10.2 Business Description
- 13.10.3 Products and Services
- 13.10.4 Financial Overview
- 13.10.5 SWOT Analysis
- 13.10.6 Key Developments
14. Appendix
14.1 About Business Market Insights
14.2 List of Abbreviations
Access the Full N Market Report
Get segment-level forecasts, regional estimates, competitive benchmarking, company profiles and downloadable Excel datasets.
